SCHEMBL82224

SCHEMBL82224

OCCCc1cccc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 3/20 0.59
HTR3B O95264 3/20 0.59
HTR3A P46098 3/20 0.59
HTR3D Q70Z44 3/20 0.59
HTR3C Q8WXA8 3/20 0.59
TAAR1 Q96RJ0 3/20 0.59
PNMT P11086 1/20 0.52
TBXA2R P21731 1/20 0.51
AOC3 Q16853 1/20 0.50
PLAAT3 P53816 1/20 0.49
PLAAT5 Q96KN8 1/20 0.49
PLAAT2 Q9NWW9 1/20 0.49
PLAAT4 Q9UL19 1/20 0.49
CHRM2 P08172 1/20 0.47
CYP3A4 P08684 1/20 0.47
IDO1 P14902 1/20 0.47
AGXT P21549 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1047900 0.94 HTR3E (0.58) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL7740676 0.92 HTR3E (0.56) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL1046534 0.92 HTR3E (0.56) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3030059 0.92 HTR3E (0.56) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL5584322 0.89 TBXA2R (0.58) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL625264 0.87 TAAR1 (0.63) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL5241228 0.87 TAAR1 (0.68) HTR3EHTR3BHTR3AHTR3DHTR3C
Hydrochloric Acid SCHEMBL7753581 0.85 TAAR1 (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL31567921 0.85 TAAR1 (0.65) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL241880 0.84 CYP4F2 (0.53) TAAR1TBXA2RMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112980895-B Enzymatic synthesis method of (R) -3-chloropropanol 宿迁阿尔法科技有限公司 2023-09-26 CN claimed
CN-108383703-B 3' -chlorophenylpropanol synthesis process 兰州紫东药业有限公司 2021-08-03 CN claimed
CN-112980895-A Enzymatic synthesis method of (R) -3-chlorophenylpropanol 宿迁阿尔法科技有限公司 2021-06-18 CN claimed
CN-112708641-A Chemical-enzymatic synthesis method of tomoxetine 上海医药工业研究院 2021-04-27 CN claimed
CN-102584536-B Method for asymmetrically catalyzing and synthesizing (R)-(+)-3-chlorine-phenylpropanol GUANGXI XINJING TECHNOLOGY CO LTD 2014-06-11 CN claimed
CN-102584536-A Method for asymmetrically catalyzing and synthesizing (R)-(+)-3-chlorine-phenylpropanol GUANGXI XINJING TECHNOLOGY CO LTD 2012-07-18 CN claimed
WO-2000037425-A1 METHOD FOR PRODUCING FLUOXETIN SIEGFRIED CMS AG (CH) 2000-06-29 WO claimed
EP-0743940-A1 NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT Astra Aktiebolag (SE) 1996-11-27 EP claimed
WO-1995021821-A1 NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT ASTRA AKTIEBOLAG (SE) 1995-08-17 WO claimed
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-05-23 US disclosed
US-20240150318-A1 PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS THE SCRIPPS RESEARCH INSTITUTE 2024-05-09 US disclosed
EP-4356971-A2 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2024-04-24 EP disclosed
EP-4352040-A1 PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS The Scripps Research Institute (US) 2024-04-17 EP disclosed
CN-117794896-A Protease inhibitors for the treatment of coronavirus infections 斯克里普斯研究学院 2024-03-29 CN disclosed
EP-0025192-B1 SUBSTITUTED OXIRANE CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1983-05-11 EP disclosed
US-4324796-A HYPOGLYCEMIC AGENTS, HYPOKETONEMIC AGENTS BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1982-04-13 US disclosed
EP-0025192-A2 Substituted oxirane carboxylic acids, process for their preparation, their use and medicines containing them Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1981-03-18 EP disclosed
US-4242347-A Hypotensive indolylalkylpiperidyl guanidines and isoureas CIBA-GEIGY CORPORATION (US) 1980-12-30 US disclosed
US-4147786-A HYPOTENSIVE CIBA-GEIGY CORPORATION (US) 1979-04-03 US disclosed
US-4073911-A ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1978-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 HTR3E 2823/4885HTR3B 1795/4885HTR3A 2866/4885
US-20240150318-A1 PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS ACE, ACE2, TMPRSS2 HTR3E 968/4885HTR3B 738/4885HTR3A 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.